Is Marker Therapeutics Stock a Good Investment?
Marker Therapeutics Investment Advice | MRKR |
- Examine Marker Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Marker Therapeutics' leadership team and their track record. Good management can help Marker Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Marker Therapeutics' business and its evolving consumer preferences.
- Compare Marker Therapeutics' performance and market position to its competitors. Analyze how Marker Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Marker Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Marker Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Marker Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Marker Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Marker Therapeutics Stock
Researching Marker Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company outstanding shares are owned by corporate insiders. The book value of Marker Therapeutics was now reported as 1.58. The company recorded a loss per share of 1.05. Marker Therapeutics last dividend was issued on the 16th of September 2016. The entity had 1:10 split on the 27th of January 2023.
To determine if Marker Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Marker Therapeutics' research are outlined below:
| Marker Therapeutics had very high historical volatility over the last 90 days | |
| Marker Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.31 M. Net Loss for the year was (14.05 M) with loss before overhead, payroll, taxes, and interest of (17.13 M). | |
| Marker Therapeutics currently holds about 18.08 M in cash with (16.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| Roughly 12.0% of the company outstanding shares are owned by corporate insiders |
Marker Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Marker Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Marker Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Marker Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 29.09 M.Marker Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (2.78) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.97) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.97.Determining Marker Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Marker Therapeutics is a good buy. For example, gross profit margin measures Marker Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Marker Therapeutics' profitability and make more informed investment decisions.
Basic technical analysis of Marker Stock
As of the 29th of November, Marker Therapeutics secures the Mean Deviation of 5.21, downside deviation of 5.7, and Risk Adjusted Performance of 0.0429. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Marker Therapeutics, as well as the relationship between them. Please verify Marker Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Marker Therapeutics is priced some-what accurately, providing market reflects its recent price of 3.19 per share. Given that Marker Therapeutics has jensen alpha of 0.1795, we recommend you to check Marker Therapeutics's last-minute market performance to make sure the company can sustain itself at a future point.Marker Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Marker Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Marker Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Marker Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marker Therapeutics' Outstanding Corporate Bonds
Marker Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Marker Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Marker bonds can be classified according to their maturity, which is the date when Marker Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MARKEL P 5 Corp BondUS570535AQ71 | View | |
| MARKEL P 35 Corp BondUS570535AR54 | View | |
| MARKEL P 43 Corp BondUS570535AS38 | View |
Understand Marker Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Marker Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0429 | |||
| Market Risk Adjusted Performance | 0.2912 | |||
| Mean Deviation | 5.21 | |||
| Semi Deviation | 5.51 | |||
| Downside Deviation | 5.7 | |||
| Coefficient Of Variation | 2256.72 | |||
| Standard Deviation | 7.1 | |||
| Variance | 50.35 | |||
| Information Ratio | 0.0266 | |||
| Jensen Alpha | 0.1795 | |||
| Total Risk Alpha | (0.76) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.2812 | |||
| Maximum Drawdown | 37.38 | |||
| Value At Risk | (11.09) | |||
| Potential Upside | 8.87 | |||
| Downside Variance | 32.47 | |||
| Semi Variance | 30.34 | |||
| Expected Short fall | (6.62) | |||
| Skewness | 1.03 | |||
| Kurtosis | 2.53 |
| Risk Adjusted Performance | 0.0429 | |||
| Market Risk Adjusted Performance | 0.2912 | |||
| Mean Deviation | 5.21 | |||
| Semi Deviation | 5.51 | |||
| Downside Deviation | 5.7 | |||
| Coefficient Of Variation | 2256.72 | |||
| Standard Deviation | 7.1 | |||
| Variance | 50.35 | |||
| Information Ratio | 0.0266 | |||
| Jensen Alpha | 0.1795 | |||
| Total Risk Alpha | (0.76) | |||
| Sortino Ratio | 0.0332 | |||
| Treynor Ratio | 0.2812 | |||
| Maximum Drawdown | 37.38 | |||
| Value At Risk | (11.09) | |||
| Potential Upside | 8.87 | |||
| Downside Variance | 32.47 | |||
| Semi Variance | 30.34 | |||
| Expected Short fall | (6.62) | |||
| Skewness | 1.03 | |||
| Kurtosis | 2.53 |
Consider Marker Therapeutics' intraday indicators
Marker Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Marker Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Marker Therapeutics time-series forecasting models is one of many Marker Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Marker Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Marker Stock media impact
Far too much social signal, news, headlines, and media speculation about Marker Therapeutics that are available to investors today. That information is available publicly through Marker media outlets and privately through word of mouth or via Marker internal channels. However, regardless of the origin, that massive amount of Marker data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Marker Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Marker Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Marker Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Marker Therapeutics alpha.
Marker Therapeutics Corporate Management
| Gerald Garrett | Senior Operations | Profile | |
| Juan MD | COO, CoFounder | Profile | |
| Peter MBA | CEO Pres | Profile | |
| Nadia Agopyan | Senior Affairs | Profile | |
| Monic MD | Chief Officer | Profile | |
| Michael Loiacono | Treasurer Secretary | Profile |
Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.